ALK+ lymphoma: Clinico-pathological findings and outcome

Blood

Volumn 93, Issue 8, 1999, Pages 2697-2706

  Falini, Brunangelo ^a   Pileri, Stefano ^b   Zinzani, Pier Luigi ^b   Carbone, Antonino ^b   Zagonel, Vittorina ^b   Wolf Peeters, Chris ^b   Verhoef, Gregor ^b   Menestrina, Fabio ^b   Todeschini, Giuseppe ^b   Paulli, Marco ^b   Lazzarino, Mario ^b   Giardini, Roberta ^b   Aiello, Antonella ^b   Foss, Hans Dieter ^b   Araujo, Iguacyra ^b   Fizzotti, Marco ^b   Pelicci, Pier Giuseppe ^b   Flenghi, Leonardo ^b   Martelli, Massimo F ^b   Santucci, Antonella ^b  

^a Istituto di Ematologia   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE;

ADULT; ARTICLE; CANCER SURVIVAL; DIAGNOSTIC VALUE; ENZYME ASSAY; ENZYME LOCALIZATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; T CELL LYMPHOMA; TUMOR BIOPSY;

ADULT; ANTIGENS, CD30; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL; MALE; PROGNOSIS; PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0033561433     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Murphy SB: Pediatric lymphomas. Recent advances and commentary on Ki-1 positive anaplastic large cell lymphomas of childhood. Ann Oncol 5:31, 1994
2. Sandlund JT, Pui CP, Santana VM, Mahmoud H, Roberts M, Morris S, Raimondi S, Ribeiro R, Crist WM, Lin JS, Mao L, Berard CW, Hutchison RE: Clinical features and treatment outcome for children with CD30+ large cell non-Hodgkin's lymphoma. J Clin Oncol 12:895, 1994
3. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K: The expression of Hodgkin's disease associated Ki-1 in reactive and neoplastic lymphoid tissues: Evidence that Sternberg-Reed cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848, 1985
4. Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki-1) molecule: A new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 85:1, 1995
5. Kadin ME, Sako D, Berliner N, Franklin W, Woda B, Borowitz M, Ireland K, Schweid A, Herzog P, Lange B, Dorfman R: Chilhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood 68:1042, 1986
6. Greer JP, Kinney MC, Collins RD, Salhany KE, Wolff SN, Hainsworth JD, Flexner JM, Stein RS: Clinical features of 31 patients with Ki-1 anaplastic large cell lymphoma. J Clin Oncol 9:539, 1991
7. Vecchi V, Burnelli R, Pileri S, Rosito P, Sabattini E, Civino A, Pericoli R, Paolucci G: Anaplastic large cell lymphoma (Ki-1/CD30+) in childhood. Med Pediatr Oncol 21:402, 1993
8. Kadin ME: Primary Ki-1 positive anaplastic large cell lymphoma: A distinct clinicopathologic entity. Ann Oncol 5:25, 1994
9. Pileri S, Bocchia M, Baroni CD, Martelli M, Falini B, Sabattini E, Gherlinzoni F, Amadori S, Poggi S, Mazza P, Burgio V, Zinzani PL, Melilli G, Benni M, Saragoni L, Martelli MF, Stein H, Mandelli F, Tura S: Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases. Br J Haematol 86:513, 1994
10. Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, Yakisan E, Dopfer R, Bucsky P, Mann G, Gadner H, Riehm H: Successful treatment strategy for Ki-1 anaplastic large cell lymphoma of childhood. A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 12:899, 1994
11. Zinzani PL, Bendandi M, Martelli M, Falini B, Sabattini E, Amadori S, Gherlinzoni F, Martelli MF, Mandelli F, Tura S, Pileri S: Anaplastic large cell lymphoma: Clinical and prognostic evaluation of 90 adult patients. J Clin Oncol 14:955, 1996
12. The non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909, 1997
13. Tilly H, Gaulard P, Lepage E, Dumontet C, Diebold J, Plantier I, Berger F, Symann M, Petrella T, Lederlin P, Briere J, for the Groupe d'Etudes des Lymphomes de l' Adulte: Primary anaplastic large-cell lymphoma in adults: Clinical presentation, immunophenotype, and outcome. Blood 90:3727, 1997
14. Stansfeld A, Diebold J, Kapanci Y, Kelenyi G, Lennert K, Mioduszewska O, Noel H, Rilke F, Sundstrom C, Van Unnik J, Wright D: Updated Kiel classification for lymphomas. Lancet 1:292, 1988
15. Harris NL, Jaffe ES, Stein H, Banks P, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Ralfkier E, Warnke RA: A Revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
16. Mason DY, Bastard C, Rimokh R, Dastugue N, Huret J-L, Kristoffersson U, Magaud J-P, Nezelof C, Tilly H, Vannier J-P, Hemet J, Warnke R: CD30-positive large cell lymphomas (Ki-1 lymphoma) are associated with a chromosomal translocation involving 5q35. Br J Haematol 74:161, 1990
17. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263:1281, 1994
18. Ladanyi M: The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma. Cancer Surv 30:59, 1997
19. Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mon S: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9:1567, 1994
20. Morris SW, Naeve C, Mathew P, Kirstein MN, Cui X, Witte DP: ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural-specific receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175, 1997
21. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B, Yamamoto T: Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14:439, 1997
22. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T: Characterization of the transforming activity of p80 a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 93:4181, 1996
23. Bischof D, Pulford K, Mason DY, Morris SW: Role of nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic kinase fusion protein in oncogenesis. Mol Cell Biol 17:2312, 1997
24. Kuefer MU, Look AT, Pulford K, Behm FG, Pattengale PK, Mason DY, Morris SW: Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 90:2901, 1997
25. Mason DY, Pulford K, Bischof D, Kuefer MU, Butler LH, Lamant L, Delsol G, Morris S: Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase tyrosine kinase is not required for malignant transformation. Cancer Res 58:1057, 1998
26. Shiota M, Fujimoto J, Takenaga M, Satoh H, Ichinohasama R, Abe M, Nakano M, Yamamoto T, Mori S: Diagnosis of t(2;5) (p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 84:3648, 1994
27. Hutchinson RE, Banki K, Shuster JJ, Barrett D, Dieck C, Berard CW, Murphy SB, Link MP, Pick Te, Laver J, Schwenn M, Mathew P, Morris SW: Use of an anti-ALK antibody in the characterization of anaplastic large-cell lymphoma of childhood. Ann Oncol 8:37, 1997
28. Pulford K, Lamant L, Morris S, Butler LH, Wood KM, Stroud D, Delsol G, Mason DY: Detection of ALK and NPM-ALK protein in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394, 1997
29. Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri S, Delsol G, Carbone A, Paulli M, Magrini U, Menestrina F, Giardini R , Pilotti S, Mezzelani A, Ugolini B, Billi M, Pucciarini A, Pacini R, Pelicci PG, Flenghi L: ALK expression defines a distinct group of T/Null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 153:875, 1998
30. Delsol G, Lamant L, Mariamé B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, Al Saati T, Cerretti DP, Morris SW, Mason DY: A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 89:1483, 1997
31. Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, Haralambieva E, Pulford K, Pileri S, Morris S, Mason DY, Delsol G: ALK-positive lymphoma: A single disease with a broad spectrum of morphology. Blood 91:2076, 1998
32. Nakamura S, Shiota M, Nakagawa A, Yatabe Y, Kojima M, Motoori T, Suzuki R, Kagami Y, Ogura M, Morishima Y, Mizoguchi Y, Okamoto M, Seto M, Koshikawa T, Mori S, Suchi T: Anaplastic large cell lymphoma: A distinct molecular pathologic entity: A reappraisal with special reference to p80(NPM/ALK) expression. Am J Surg Pathol 21:1420, 1997
33. Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A, Ladanyi M, Jhanwar S, Dalla-Favera R, Chaganti RSK: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 331:74, 1994
34. NPM/ALK: A distinct clinicopathologic entity. Blood 86:1954, 1995
35. NPM/ALK. Leuk Lymphoma 23:25, 1996
36. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987, 1993
37. Shipp M: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high risk" disease? Blood 83:1165, 1994
38. Pileri S, Falini B, Delsol G, Stein H, Baglioni P, Poggi S, Martelli MF, Rivano MT, Mason DY, Stansfeld AG: Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1+) with a high content of reactive histiocytes. Histopathology 16:383, 1990
39. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME: A small cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 17:859, 1993
40. Pileri SA, Mason DY, Mori S, Pulford K, Sabattini E, Roncador G, Piccaluga PP, Stein H, Falini B: Frequent expression of the p80 NPM-ALK chimeric fusion protein in anaplastic large cell lymphoma, lympho-histiocytic type. Am J Pathol 150:1207, 1997
41. Kadin ME: Anaplastic large cell lymphoma and its morphological variants. Cancer Surv 30:77, 1997
42. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H, Mason DY: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219, 1994
43. Falini B, Flenghi L, Pileri S, Gambacorta M, Bigerna B, Durkop H, Eitelbach F, Thiele J, Pacini R, Cavaliere A, Martelli M, Cardarelli N, Sabattini E, Poggi S, Stein H: PG-M1: A new monoclonal antibody directed against a fixative-resistant epitope on the macrophage-restricted form of the CD68 molecule. Am J Pathol 142:1359, 1993
44. Pileri S, Roncador G, Ceccarelli C, Piccioli M, Briskomatis A, Sabattini E, Ascani S, Santini D, Piccaluga PP, Leone O, Damiani S, Ercolessi C, Sandri F, Pieri F, Leoncini L, Falini B: Antigen retrieval techniques in immunohistochemistry: Comparison of different methods. J Pathol 183:116, 1997
45. Ponder BA, Wilkinson WN: Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry. J Histochem Cytochem 29:981, 1981
46. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
47. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
48. Cox DR: Regression models and life-tables. J R Stat Soc 34:187, 1972
49. Wlodarska I, De Wolf-Peeters C, Falini B, Verhoef G, Morris SW, Hagemeijer A, Van den Berghe H: The cryptic inv(2) (p23q35) defines a new molecular genetic subtype of ALK-positive ALCL. Blood 92:2688, 1998
50. Fraga M, Brousset P, Schlaifer D, Payen C, Robert A, Rubie H, Huguet-Rigal F, Delsol G: Bone marrow involvement in anaplastic large cell lymphoma. Immunocytochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 103:82, 1995
51. Fanin R, Silvestri P, Geromin A, Cerno M, Infanti I, Zaja F, Barillari G, Savignano C, Rinaldi C, Damiani D, Buffoli A, Biffoni F, Baccarani M: Primary systemic CD30(Ki-1)-positive anaplastic large cell lymphoma of the adult:sequential intensive treatment with F-MACHOP regimen (± radiotherapy) and autologous bone marrow transplantation. Blood 87:1243, 1996
52. Chakravarti V, Kamani NR, Bayever E, Lange B, Herzog P, Sanders JE, August CS: Bone marrow transplantation for chilhood Ki-1 lymphoma. J Clin Oncol 8:657, 1990
53. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Durkop H, Aversa F, Corneli P, Pizzolo G, Barbabietola G, Sabattini E, Pileri S, Martelli MF, Stirpe F: Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339:1195, 1992
54. Pasqualucci L, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito L, Falini B, Kadin MA: Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large cell lymphoma. Blood 85:2139, 1995
55. Uckun FM, Evans WE, Forsyth CJ: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19 associated kinases. Science 267:886, 1995
56. Bolen JB, Brugge JS: Leukocyte protein tyrosine kinases: Potential targets for drug discovery. Annu Rev Immunol 15:371, 1997
57. Chou W-C, Su I-J, Tien H-F, Liang D-C, Wang C-H, Chang Y-C, Cheng A-L: Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphomas. Special emphasis on the tumor response to 13-cis retinoid acid. Cancer 78:1805, 1996